Drug Search Results
More Filters [+]

GSK-2036874A

Alternative Names: GSK-2036874A, GSK2036874A, GSK 2036874A, GSK-2036874, GSK2036874, GSK 2036874
Latest Update: 2019-10-01
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2036874A

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis B|Diphtheria|Tetanus|Influenza, Human|Poliomyelitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01106092

P2

Completed

Influenza, Human|Diphtheria|Tetanus|Hepatitis B|Poliomyelitis

2010-09-02

Recent News Events

Date

Type

Title